APA (7th ed.) Citation

AG, G., M, A., A, K., DR, I., HY, H., N, S., . . . EC, D. (2025). Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers. Journal of the National Cancer Institute, 117(1), 188. https://doi.org/10.1093/jnci/djae224

Chicago Style (17th ed.) Citation

AG, Goglia, et al. "Pan-cancer Genomic Analysis Reveals FOXA1 Amplification Is Associated with Adverse Outcomes in Non-small Cell Lung, Prostate, and Breast Cancers." Journal of the National Cancer Institute 117, no. 1 (2025): 188. https://doi.org/10.1093/jnci/djae224.

MLA (9th ed.) Citation

AG, Goglia, et al. "Pan-cancer Genomic Analysis Reveals FOXA1 Amplification Is Associated with Adverse Outcomes in Non-small Cell Lung, Prostate, and Breast Cancers." Journal of the National Cancer Institute, vol. 117, no. 1, 2025, p. 188, https://doi.org/10.1093/jnci/djae224.